12.07.2015 Views

Hulya Wieshmann - PET / CT

Hulya Wieshmann - PET / CT

Hulya Wieshmann - PET / CT

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>PET</strong> <strong>CT</strong> inOesophagealCancerH <strong>Wieshmann</strong>, R Hanlon, D White,K Nash, N AlamDepartment of RadiologyUniversity Hospital Aintree


Objectives• Background information about the <strong>PET</strong> <strong>CT</strong> services• Update on <strong>PET</strong> <strong>CT</strong> services in Liverpool• Impact of <strong>PET</strong> <strong>CT</strong> in the staging of oesophagealcancer -12 months experience at UHA• Strengths and Limitations• Future developments


UK <strong>PET</strong>-<strong>CT</strong>Advisory Board & Department of HealthFinal Version February 2009<strong>PET</strong>-<strong>CT</strong> Likely demand


Indications for NW Q2 Jul-Sep 080%5%0% 3% 2%3%Head and Neck(Parotid/Oropharynx/Larynx/Thyroid/Parathyroid)LungOesophagus10%Upper GI (Stomach/Small Bowel/Liver/Pancreas)Breast1%1%ColorectalGynaecological (Ovary/Uterus/Cervix)13%Lymphoma62%SarcomaUnknown PrimaryOther


6%1%5% 0%5%Indications for NW Q3 Oct-Dec 08Head and Neck(Parotid/Oropharynx/Larynx/Thyroid/Parathyroid)1%1%LungOesophagus11%Upper GI (Stomach/Small Bowel/Liver/Pancreas)ColorectalUrological (Renal/Adrenal/Bladder/Prostate/Testicle)1%Gynaecological (Ovary/Uterus/Cervix)Lymphoma14%55%SarcomaUnknown PrimaryOther


Referrals from NW Trusts15%Aintree UH0%28%CCOCountess of Chester7%<strong>CT</strong>CMid-Cheshire6%North CheshireRLBUHT7%8%Southport & OrmskirkSt Helens & Knowsley7%0%14%8%Walton CentreWUTH


Numbers120100806040200Referrers to NW <strong>PET</strong>ReferrersLedson, M J Liverpool Heart and Chest HospitalM agennis, RF North CheshireM aguire, J Clatterbridge Centre for OncologyWalker, P Aintree UHSturgess, RP Aintree UHPoston, GJ Aintree UHSmyth, CM Liverpool Heart and Chest HospitalHendry, J St Helens and KnowsleyBenton, I Countess of ChesterCorless, J Wirral University Teaching HospitalFinnerty, JP Countess of ChesterWarburton, CJ Aintree UHLawrence, DS Wirral University Teaching HospitalStevenson, N Wirral University Teaching HospitalSmart, HL RLBUHTYouzguin, A Southport and OrmskirkLancaster, J Aintree UHShackcloth, M St Helens and KnowsleyM cM anus, CJ Southport and OrmskirkWahbi, ZK Wirral University Teaching HospitalScott, S Countess of ChesterJackson, SR Aintree UHTwite, S St Helens and KnowsleyBarben, CP Aintree UHEvans, J Countess of ChesterM alik, HZ Aintree UHAngus, RM Aintree UHRoland, NJ Aintree UHSmyth, CM RLBUHTStockton, PA St Helens and KnowsleyPage, RD Liverpool Heart and Chest HospitalM aguire, J Liverpool Heart and Chest Hospital


North West Upper GI Clinical Coding 2008-200910%2%3%StagingRestagingRecurrenceFollow-Up85%


North West Referring Hospitals 2008-0913%Aintree UH13%31%Cardiothoracic Centre, LiverpoolClatterbridge Centre for OncologyCountess Of Chester17%17%33%Liverpool Heart and Chest HospitalNobles Hospital IOMNorth CheshireRLBUHTSouthport and OrmskirkSt Helens and Knowsley1%2%20%1%Warrington HospitalWhiston Hospital2%7%20%3%1%2%


FDG <strong>PET</strong><strong>CT</strong> for Oesophageal Cancer•All patients suitable for resection•All patients pre and post neo adjuvant therapy


April 2008-March 2009 Upper GIMDT at Aintree– 313 New diagnosis upper GI Ca– 148 newly diagnosed oesophageal cancer» Oesophageal resection 30


<strong>PET</strong> <strong>CT</strong> Audit Data Analysis• N = 51• Mean age =65.4 years• Female/Male=11/40 (22/78%)


Tumour site• Proximal intrathoracic oesophagus - 1(2%)• Middle intrathoracic oesophagus - 7(13.7%)• Distal intrathoracic oesophagus - 24(47%)• Junctional tumour - 19 (37.3%)


TNM staging on EUS29 Patients investigated with EUS– T1 - 2 (7%)– T2 - 11 (38%)– T3 - 15 (52%)– T4 - 1 (3%)– N0 - 17 (59%)– N1 - 12 (41%)– 2 examinations found M1 positive disease – 2 (7%)


TNM Classification on <strong>CT</strong>– T 1 / 2 disease - 2 (3.3%)– T 2 / 3 disease - 41 (80%)– T4 disease - 7 (13.7%)– N 0 disease - 16 (31.3%)– N 1 disease - 34 (66.6%)– M 0 disease - 39 (76.5%)– M 1a disease - 6 (12%)– M1b disease - 5 (10%)


N M staging on <strong>PET</strong><strong>CT</strong>– N0 - 27 (53%)– N1 - 24 (47%)– M0 - 37 (72.5%)– M1a - 4 (8%)– M1b - 10 (19.5%)


<strong>PET</strong> <strong>CT</strong> compared with <strong>CT</strong> staging– Up in 12 (24%)–Down in 13 (25%)»No change 26 (51%)


!%%.425,70/9&$4734/,/80,80– &53– 433» 4.,303


Conclusion• <strong>PET</strong> <strong>CT</strong> has a complementary role inpatients with Oesophageal cancer.• In our cohort FDG <strong>PET</strong> <strong>CT</strong> identified 9patients with M1B disease and preventedunnecessary surgery


Incidental Findings on <strong>PET</strong><strong>CT</strong>• Oropharyngeal activity• Focal Thyroid activity• Focal Oesophageal activity• Focal colonic activity


Future• Static <strong>PET</strong> <strong>CT</strong> in Liverpool• Contrast-Enhanced 18F-FDG <strong>PET</strong>/<strong>CT</strong>:1-Stop-Shop Imaging for Assessing theResectability


:9:70Static <strong>PET</strong> <strong>CT</strong> in LiverpoolContrast-Enhanced 18F-FDG<strong>PET</strong>/<strong>CT</strong>: 1-Stop-Shop Imagingfor Assessing the Resectability


%,34:

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!